Bharathi Muthusamy, Mehmet Berktas, Jingyi Li, Darren S Thomas, Ping Sun, Aliki Taylor, Nathan A Pennell
{"title":"I-III期非小细胞肺癌的表皮生长因子受体突变检测、治疗和生存率：CancerLinQ Discovery数据库回顾性分析。","authors":"Bharathi Muthusamy, Mehmet Berktas, Jingyi Li, Darren S Thomas, Ping Sun, Aliki Taylor, Nathan A Pennell","doi":"10.1080/14796694.2024.2347826","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> To describe real-world biomarker testing, treatment and survival in stage IA-IIIC non-small cell lung cancer (NSCLC).<b>Methods:</b> Electronic records of USA-based patients in the CancerLinQ Discovery<sup>®</sup> database with stage IA-IIIC NSCLC (diagnosed between 2014 and 2018) were screened; a curated cohort of 14,452 records was identified for further analysis.<b>Results:</b> Of 3121 (21.6%) patients who had <i>EGFR</i> testing, 493 (15.8%) were <i>EGFR-</i>mutation positive. Of 974 patients who underwent surgical resection, 513 (52.7%) received adjuvant therapy. A quarter of patients with <i>EGFR-</i>mutation positive NSCLC received targeted adjuvant therapy.<b>Conclusion:</b> Approximately a fifth of patients underwent <i>EGFR</i> testing; biomarker testing is important to ensure optimal outcomes for patients with stage I-III NSCLC.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11497985/pdf/","citationCount":"0","resultStr":"{\"title\":\"<i>EGFR</i> mutation testing, treatment and survival in stage I-III non-small cell lung cancer: CancerLinQ Discovery database retrospective analysis.\",\"authors\":\"Bharathi Muthusamy, Mehmet Berktas, Jingyi Li, Darren S Thomas, Ping Sun, Aliki Taylor, Nathan A Pennell\",\"doi\":\"10.1080/14796694.2024.2347826\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Aim:</b> To describe real-world biomarker testing, treatment and survival in stage IA-IIIC non-small cell lung cancer (NSCLC).<b>Methods:</b> Electronic records of USA-based patients in the CancerLinQ Discovery<sup>®</sup> database with stage IA-IIIC NSCLC (diagnosed between 2014 and 2018) were screened; a curated cohort of 14,452 records was identified for further analysis.<b>Results:</b> Of 3121 (21.6%) patients who had <i>EGFR</i> testing, 493 (15.8%) were <i>EGFR-</i>mutation positive. Of 974 patients who underwent surgical resection, 513 (52.7%) received adjuvant therapy. A quarter of patients with <i>EGFR-</i>mutation positive NSCLC received targeted adjuvant therapy.<b>Conclusion:</b> Approximately a fifth of patients underwent <i>EGFR</i> testing; biomarker testing is important to ensure optimal outcomes for patients with stage I-III NSCLC.</p>\",\"PeriodicalId\":12672,\"journal\":{\"name\":\"Future oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11497985/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14796694.2024.2347826\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/6/25 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2024.2347826","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/25 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
EGFR mutation testing, treatment and survival in stage I-III non-small cell lung cancer: CancerLinQ Discovery database retrospective analysis.
Aim: To describe real-world biomarker testing, treatment and survival in stage IA-IIIC non-small cell lung cancer (NSCLC).Methods: Electronic records of USA-based patients in the CancerLinQ Discovery® database with stage IA-IIIC NSCLC (diagnosed between 2014 and 2018) were screened; a curated cohort of 14,452 records was identified for further analysis.Results: Of 3121 (21.6%) patients who had EGFR testing, 493 (15.8%) were EGFR-mutation positive. Of 974 patients who underwent surgical resection, 513 (52.7%) received adjuvant therapy. A quarter of patients with EGFR-mutation positive NSCLC received targeted adjuvant therapy.Conclusion: Approximately a fifth of patients underwent EGFR testing; biomarker testing is important to ensure optimal outcomes for patients with stage I-III NSCLC.
期刊介绍：
Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community.
The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
